#LanAnhHandmade #youtube My name is Lan Anh, owner of youtube channel LanAnhHandmade. I live in Vietnam, a country in ...

Astellas Pharma has agreed to co-develop and co-commercialize Vir Biotechnology’s most advanced immuno-oncology asset, the prostate cancer candidate VIR-5500, through a collaboration that could ...

There are hundreds of biotechnology companies today that have never commercialized a drug. For many years, the standard approach in the industry has been to advance the science, prove the asset, and ...

Lizzi C. Lee is a fellow on the Chinese economy at Asia Society Policy Institute’s Center for China Analysis (CCA), based in Washington DC, USA. Jing Qian is vice-president of the Asia Society and ...

Feb 4 (Reuters) - Biotech firm Bio-Techne (TECH.O), opens new tab beat analysts' estimates for second-quarter revenue and profit on Wednesday, helped by robust demand for its products used in drug ...

For years, public debate around U.S. dependence on China has focused on semiconductors, consumer electronics, rare earth minerals and industrial manufacturing. Far less attention has been paid to a ...

Arthur Herman’s op-ed, “America Is the Sole Superpower Again,” (Jan. 15) asserts that China is “sliding into a distant second place” in the battle for economic, military and technological supremacy.

As a veteran who was wounded during a mortar attack in Iraq, I’m all too familiar with the fact that our enemies can hit us with little warning. I’ve seen firsthand what happens when we underestimate ...

Why personalized gene editing, genetic resurrections and embryo scoring made our list. Earlier this week, MIT Technology Review published its annual list of Ten Breakthrough Technologies. As always, ...

Biotech IPOs hit lowest level in over a decade in 2025 Investors focus on biotechs with mature pipelines and positive trial data Lower interest rates and capital inflows expected to boost sector Jan ...

The green shoots suggesting a comeback was in sight for biotech stocks last year have mostly grown into proverbial flowering plants—but one company’s precipitous year-over-year decline in market ...

So, what will the early months of 2026 look like for the biotech sector? First, let me say that the biotech sector being 'en fuego' over the past three quarters has made my year as far as my portfolio ...